IpIBA seminar series 2022/2023 “Intravenous delivery of BCG into the lung enables antitumor immunity”

Tuesday, December 13th 2022 From 9:30 to 10:30

Administration of BCG into the bladder was one of the first immunotherapies approved by the FDA and nowadays is still the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Recently, it was shown that systemic administration of BCG by the intravenous (IV) route is well-tolerated and highly effective at preventing tuberculosis infection in a Rhesus macaque model. Here, we show that systemic administration of BCG by the IV route in a therapeutic scenario slows tumor growth and extends mouse survival in mouse models of B16-F10 lung metastasis and in an orthotopic LLC lung cancer model by enhancing both antitumoral innate and adaptive immune responses.

Place:

CIBA, main meeting room, and online via zoom.

Importante las plazas son limitadas: 100 presencial y 100 modalidad on line. Si participa de forma presencial no hace falta realizar inscripción on line.